Houston Methodist Hospital

1. Merck Sharp & Dohme Corporation $1,552,692 34 payments
2. Novartis Pharmaceuticals Corporation $1,113,160 20 payments
3. Pfizer Inc. $504,433 28 payments
4. E.R. Squibb & Sons, L.L.C. $239,363 22 payments
5. Boehringer Ingelheim International GmbH $151,536 10 payments
6. Shockwave Medical, Inc $106,281 11 payments
7. Boehringer Ingelheim Pharmaceuticals, Inc. $98,736 17 payments
8. Incyte Corporation $77,459 76 payments
9. TransMedics, Inc. $60,748 19 payments
10. Roche Diagnostics Operations, Inc. $51,954 8 payments

1. A Phase 3 Openlabel Study of Elranatamab Monotherapy Versus Elotuzumab Pomalidomide Dexamethasone Epd Or Pomalidomide Bortezomib Dexamethasone PVD Or Carfilzomib Dexamethasone KD in Participants With Relapsedrefractory Multiple Myeloma Who Received Prior Anticd38 Directed Therapy $493,227 23 payments
2. Liver Transplant Patients $416,047 2 payments
3. Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Pembrolizumab in Metastatic Triple Negative Breast Cancer and Metastatic Squamous Non-Small Cell Lung Cancer $398,829 2 payments
4. Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Pembrolizumab in Metastatic Triple Negative Breast Cancer and Metastatic Squamous Non-Small Cell Lung Cancer $331,166 2 payments
5. A Randomized, Double-Blind, Phase III Study, Comparing Nis793 in Combination With Gemcitabine and Nab-Paclitaxel Versus (VS.) Placebo Combined With Gemcitabine and Nab-Paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (MPD $199,925 1 payment
6. An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50 Metastatic Non-small Cell Lung Cancer KEYNOTE D46,EVOKE-03. $191,075 3 payments
7. A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 $185,785 4 payments
8. A Randomized, Open-Label, Phase II Study of Canakinumab Or Pembrolizumab As Monotherapy Or in Combination As Neoadjuvant Therapy in Subjects With Resectable Non-Small Cell Lung Cancer (Canopy-N) $155,692 3 payments
9. Pharmacokinetic Analysis of Once-Daily Zortress (Everolimus) and Extended-Release Tacrolimus in Rental Transplant Recipients $150,225 2 payments
10. Proof of Clinical Principal in Crohn?s Disease $133,577 8 payments

1. Non-patient care $12,950 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.